London
Roots Analysis has announced the addition of “Fc Protein and Glyco-engineered Antibodies Market, 2021-2030” report to its list of offerings.
Over time, a substantial body of evidence has validated the therapeutic applications of Fc engineering platforms; Fc modified antibodies have shown to augment the various immune effector functions, such as antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), antibody-dependent cellular phagocytosis (ADCP) activity and / or the half-life of the molecule
To order this 250+ page report, which features 100+ figures and 110+ tables, please visit https://www.rootsanalysis.com/reports/fc-protein-engineered-and-glycoengineered-antibodies-market.html
Key Market Insights
The Fc engineered antibodies pipeline features more than 125 marketed drugs / drug development programs
Around 15% Fc protein and glyco-engineered antibodies are marketed, while close to 75% are being evaluated in different phases of clinical trials and 10% in preclinical studies. Examples of marketed Fc engineered antibodies include Gazvya®, Imfinzi®, MONJUVI® and Skyrizi®.
Around 30 companies claim to be engaged in the development of Fc protein and glyco-engineered antibodies
Around 55% of the aforementioned players are large companies (with more than 5000 employees). It is worth highlighting that, majority of the developers engaged in this domain (54%) are based in North America, followed by Europe (26%) and Asia-Pacific (20%).
To request a sample copy / brochure of this report, please visit this https://www.rootsanalysis.com/reports/fc-protein-engineered-and-glycoengineered-antibodies-market/request-sample.html
For additional details, please visit
or email sales@rootsanalysis.com
You may also be interested in the following titles:
Contact:
Ben Johnson
+1 (415) 800 3415
